FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3170494906> ?p ?o ?g. }

• W3170494906 endingPage "4131" @default.
• W3170494906 startingPage "4131" @default.
• W3170494906 abstract "4131 Background: Sarcopenia and sarcopenic obesity have been associated with overall survival (OS) in patients (pts) with borderline resectable and advanced pancreatic ductal adenocarcinoma (PDA), but little is known about the effect of body composition on OS in pts with resectable PDA. We examined the relationship between skeletal muscle and adipose tissue measurements on baseline computed tomography (CT) and OS of pts with resectable PDA in a secondary analysis of SWOG S1505 (NCT02562716). Methods: SWOG S1505 enrolled pts with resectable PDA who were randomized to receive neoadjuvant FOLFIRINOX or gemcitabine-nab paclitaxel, followed by surgical resection. Baseline axial CT images at the L3 level were analyzed with externally validated software and measurements were recorded for skeletal muscle area (SMA), density (SMD) and index (SMI); visceral adipose tissue area (VATA) and density (VATD); and subcutaneous adipose tissue area (SATA) and density (SATD). Sarcopenia was defined as SMI < 52 cm2/m2 for men and < 39 cm2/m2 for women; sarcopenic obesity was defined as sarcopenia and a body mass index (BMI) >30 kg/m2. The relationships between CT metrics and OS were analyzed using Cox regression models, with 95% CI. Statistical significance was defined as p < 0.05. Results: Of 98 pts with available baseline abdominal CT, 8 were excluded for scan quality, resulting in 90 evaluable cases: 51 men (57%), 39 women (43%); mean age, 63.2 years, SD 8.5; mean BMI, 29.3 kg/m2, SD 6.4; 80 (89%) White, 6 (7%) Black, and 4 (4%) unknown. Sarcopenia was present in 32 (36%) and sarcopenic obesity in 10 (11%) patients. Univariable analyses for the variables of interest indicated VATA (HR 1.24; 0.97-1.60; p = 0.09) and SMD (HR 0.75; 0.57-0.98; p = 0.04) were associated with OS. Analyses adjusted for sex, race, age, BMI, performance score, contrast use, sarcopenia, and sarcopenic obesity showed VATA was associated with OS (HR 1.58; 1.0-2.51; p = 0.05). No significant difference in median OS was observed between pts with vs. without sarcopenia (OS 23.6 [19.3-NA] vs. 27.9 months [18.6-NA], respectively). Pts with vs. without sarcopenic obesity had lower median OS: 18.6 (14.7-NA) vs. 25.1 (10.5-46.0) months, respectively, but this difference was not statistically significant (HR 1.90, 95%CI 0.81-4.47, p = 0.14). Conclusions: This is one of the first studies to systematically evaluate body composition parameters in a prospective trial of patients with resectable PDA who received neoadjuvant chemotherapy. We found that visceral fat (VATA) is a prognostic marker in this population, but that sarcopenia may not be predictive in early PDA. Further studies to define the impact of longitudinal changes in body composition on individual outcomes may provide greater precision in predicting OS for subsets of pts with pancreatic cancer. Clinical trial information: NCT02562716." @default.
• W3170494906 created "2021-06-22" @default.
• W3170494906 creator A5008330168 @default.
• W3170494906 creator A5014809735 @default.
• W3170494906 creator A5015750678 @default.
• W3170494906 creator A5015990700 @default.
• W3170494906 creator A5019995834 @default.
• W3170494906 creator A5029950314 @default.
• W3170494906 creator A5033769736 @default.
• W3170494906 creator A5039587632 @default.
• W3170494906 creator A5047818279 @default.
• W3170494906 creator A5048654505 @default.
• W3170494906 creator A5053703913 @default.
• W3170494906 creator A5062407905 @default.
• W3170494906 creator A5064726267 @default.
• W3170494906 creator A5065605420 @default.
• W3170494906 creator A5089839809 @default.
• W3170494906 creator A5091876744 @default.
• W3170494906 date "2021-05-20" @default.
• W3170494906 modified "2023-10-01" @default.
• W3170494906 title "Body composition measurements and overall survival in patients with resectable pancreatic adenocarcinoma receiving neoadjuvant chemotherapy: Analysis from SWOG S1505." @default.
• W3170494906 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.4131" @default.
• W3170494906 hasPublicationYear "2021" @default.
• W3170494906 type Work @default.
• W3170494906 sameAs 3170494906 @default.
• W3170494906 citedByCount "0" @default.
• W3170494906 crossrefType "journal-article" @default.
• W3170494906 hasAuthorship W3170494906A5008330168 @default.
• W3170494906 hasAuthorship W3170494906A5014809735 @default.
• W3170494906 hasAuthorship W3170494906A5015750678 @default.
• W3170494906 hasAuthorship W3170494906A5015990700 @default.
• W3170494906 hasAuthorship W3170494906A5019995834 @default.
• W3170494906 hasAuthorship W3170494906A5029950314 @default.
• W3170494906 hasAuthorship W3170494906A5033769736 @default.
• W3170494906 hasAuthorship W3170494906A5039587632 @default.
• W3170494906 hasAuthorship W3170494906A5047818279 @default.
• W3170494906 hasAuthorship W3170494906A5048654505 @default.
• W3170494906 hasAuthorship W3170494906A5053703913 @default.
• W3170494906 hasAuthorship W3170494906A5062407905 @default.
• W3170494906 hasAuthorship W3170494906A5064726267 @default.
• W3170494906 hasAuthorship W3170494906A5065605420 @default.
• W3170494906 hasAuthorship W3170494906A5089839809 @default.
• W3170494906 hasAuthorship W3170494906A5091876744 @default.
• W3170494906 hasConcept C121608353 @default.
• W3170494906 hasConcept C126322002 @default.
• W3170494906 hasConcept C143998085 @default.
• W3170494906 hasConcept C171089720 @default.
• W3170494906 hasConcept C2776214593 @default.
• W3170494906 hasConcept C2776694085 @default.
• W3170494906 hasConcept C2777148230 @default.
• W3170494906 hasConcept C2777328239 @default.
• W3170494906 hasConcept C2780210213 @default.
• W3170494906 hasConcept C2780221984 @default.
• W3170494906 hasConcept C2780258809 @default.
• W3170494906 hasConcept C2780962732 @default.
• W3170494906 hasConcept C2781182431 @default.
• W3170494906 hasConcept C50382708 @default.
• W3170494906 hasConcept C526805850 @default.
• W3170494906 hasConcept C71924100 @default.
• W3170494906 hasConceptScore W3170494906C121608353 @default.
• W3170494906 hasConceptScore W3170494906C126322002 @default.
• W3170494906 hasConceptScore W3170494906C143998085 @default.
• W3170494906 hasConceptScore W3170494906C171089720 @default.
• W3170494906 hasConceptScore W3170494906C2776214593 @default.
• W3170494906 hasConceptScore W3170494906C2776694085 @default.
• W3170494906 hasConceptScore W3170494906C2777148230 @default.
• W3170494906 hasConceptScore W3170494906C2777328239 @default.
• W3170494906 hasConceptScore W3170494906C2780210213 @default.
• W3170494906 hasConceptScore W3170494906C2780221984 @default.
• W3170494906 hasConceptScore W3170494906C2780258809 @default.
• W3170494906 hasConceptScore W3170494906C2780962732 @default.
• W3170494906 hasConceptScore W3170494906C2781182431 @default.
• W3170494906 hasConceptScore W3170494906C50382708 @default.
• W3170494906 hasConceptScore W3170494906C526805850 @default.
• W3170494906 hasConceptScore W3170494906C71924100 @default.
• W3170494906 hasFunder F4320332161 @default.
• W3170494906 hasIssue "15_suppl" @default.
• W3170494906 hasLocation W31704949061 @default.
• W3170494906 hasOpenAccess W3170494906 @default.
• W3170494906 hasPrimaryLocation W31704949061 @default.
• W3170494906 hasRelatedWork W2012954058 @default.
• W3170494906 hasRelatedWork W2138640290 @default.
• W3170494906 hasRelatedWork W2376347278 @default.
• W3170494906 hasRelatedWork W2599910524 @default.
• W3170494906 hasRelatedWork W2721585150 @default.
• W3170494906 hasRelatedWork W2910998150 @default.
• W3170494906 hasRelatedWork W3008650849 @default.
• W3170494906 hasRelatedWork W3046481916 @default.
• W3170494906 hasRelatedWork W3154040450 @default.
• W3170494906 hasRelatedWork W3196960728 @default.
• W3170494906 hasVolume "39" @default.
• W3170494906 isParatext "false" @default.
• W3170494906 isRetracted "false" @default.
• W3170494906 magId "3170494906" @default.
• W3170494906 workType "article" @default.